How does the extractable and leachable profile of COC cartridges compare to that of Type I glass for sensitive biologics?

COC cartridges exhibit lower extractable levels than borosilicate glass, particularly for metal ions and silicone oil. Regulatory agencies accept COC for most biologic formulations when supported by container-closure interaction studies [7]. Read More

What fill-speed limitations should buyers consider when switching from glass to polymer cartridges?

Polymer cartridges typically run 10–15% slower on legacy glass filling lines due to different thermal and friction properties. Dedicated polymer-optimized lines eliminate this gap entirely [7]. Read More

How do RTU cartridge formats affect the total cost of ownership versus bulk-washed alternatives?

RTU cartridges carry a 20–30% higher unit price but reduce facility capital, water, and energy costs by approximately EUR 1.2 million per line annually [2][12]. Read More

What qualification timeline should CDMOs expect when onboarding a new cartridge supplier?

Typical supplier qualification takes 12–18 months, covering dimensional verification, extractable studies, and stability testing under ICH guidelines [15]. Read More

Are dual-chamber cartridges gaining traction for lyophilized biologic reconstitution?

Yes — dual-chamber cartridges are growing in demand for lyophilized ADCs and vaccines requiring point-of-care reconstitution. At least four new dual-chamber device platforms entered development in 2024 [8]. Read More

How does cartridge dimensional tolerance affect device-level combination product regulatory filings?

Tighter ISO 11040 tolerances reduce device performance variability, simplifying human-factors studies required for FDA and EMA combination product approvals [17]. Read More

What role do secondary packaging innovations play in reducing cartridge breakage during cold-chain logistics?

Advanced nest-and-tub secondary packaging has cut transit breakage from 3–4% to below 0.5%, delivering measurable savings for temperature-sensitive biologic shipments [13]. Read More

Pharmaceutical Cartridges Market

ID: MRFR/Pharma/10159-HCR

128 Pages

Rahul Gotadki

Last Updated: June 22, 2026

Pharmaceutical Cartridges Market Research Report Information By Material (Glass and Plastic), By Capacity (Below 5 ml, 5-50 ml, 51-250 ml, and Above 250 ml), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Self-Administered Biologic Therapies Expansion | |
  2. 3.1.2 EU Annex 1 RTU Cartridge Mandates | |
  3. 3.1.3 GLP-1 Receptor Agonist Volume Growth | |
  4. 3.1.4 AI-Driven Fill-Finish Automation | |
  5. 3.1.5 Engineering Plastics Adoption (COC/COP) | |
  6. 3.1.6 Large-Volume Subcutaneous Delivery Expansion | |
  7. 3.1.7 Emerging-Market Insulin Pen Programs |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Glass Supply Chain Fragility and Breakage | |
  2. 3.2.2 High Capital Cost of RTU Filling Line Conversion | |
  3. 3.2.3 Regulatory Divergence Across Markets | |
  4. 3.2.4 Extractable/Leachable Concerns with Polymer Cartridges | |
  5. 3.2.5 Skilled Workforce Shortages in Aseptic Manufacturing |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Wearable On-Body Delivery Devices | |
  2. 3.3.2 Emerging-Market Insulin Access Programs | |
  3. 3.3.3 Oncology Antibody-Drug Conjugate Migration | |
  4. 3.3.4 Data-Enabled Smart Cartridge Platforms | |
  5. 3.3.5 Contract Manufacturing Capacity Expansion |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Pharmaceutical Cartridges Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Material | |
  1. 5.1.1 Glass (Type I Borosilicate and Others) | |
  2. 5.1.2 Engineering Plastics (COC/COP and Others) | |
  3. 5.1.3 Others |
2. 5.2 By Delivery Device Compatibility | |
  1. 5.2.1 Reusable Pen Injectors | |
  2. 5.2.2 Autoinjectors | |
  3. 5.2.3 Wearable On-Body Pumps | |
  4. 5.2.4 Disposable Pen Injectors |
3. 5.3 By Capacity | |
  1. 5.3.1 Below 3 mL | |
  2. 5.3.2 3 mL–5 mL | |
  3. 5.3.3 5 mL–10 mL | |
  4. 5.3.4 Above 10 mL |
4. 5.4 By Therapeutic Area | |
  1. 5.4.1 Diabetes | |
  2. 5.4.2 Oncology | |
  3. 5.4.3 Autoimmune Diseases | |
  4. 5.4.4 Ophthalmology | |
  5. 5.4.5 Others |
5. 5.5 By End User | |
  1. 5.5.1 Pharmaceutical Companies | |
  2. 5.5.2 CMOs/CDMOs | |
  3. 5.5.3 Research Institutions
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 SCHOTT AG | |
  2. 7.3.2 Gerresheimer AG | |
  3. 7.3.3 Stevanato Group | |
  4. 7.3.4 Nipro Corporation | |
  5. 7.3.5 West Pharmaceutical Services | |
  6. 7.3.6 Becton Dickinson (BD) | |
  7. 7.3.7 SGD Pharma | |
  8. 7.3.8 Corning Incorporated | |
  9. 7.3.9 Terumo Corporation | |
  10. 7.3.10 Baxter International
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Integrated Manufacturing and Digital Twins |
2. 8.2 Platform Standardization and Interoperability |
3. 8.3 Sustainability and Circular Packaging |
4. 8.4 Cell and Gene Therapy Cartridge Formats
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
1 LIST OF TABLES
2 LIST OF FIGURES

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Material	Glass (Type I and Others); Engineering Plastics (COC/COP and Others); Others	Glass	Engineering Plastics
Delivery Device Compatibility	Reusable Pen Injectors; Autoinjectors; Wearable On-Body Pumps; Disposable Pen Injectors	Reusable Pen Injectors	Wearable On-Body Pumps
Capacity	Below 3 mL; 3 mL–5 mL; 5 mL–10 mL; Above 10 mL	Below 3 mL	Above 10 mL
Therapeutic Area	Diabetes; Oncology; Autoimmune Diseases; Ophthalmology; Others	Diabetes	Oncology
End User	Pharmaceutical Cartridges Market Companies; CMOs/CDMOs; Research Institutions	Pharmaceutical Cartridges Market Companies	CMOs/CDMOs
Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Material

Sub-Segment	Key Trend
Glass (Type I Borosilicate and Others)	Continued dominance driven by regulatory acceptance and dimensional standardization for pen injector platforms
Engineering Plastics (COC/COP and Others)	Accelerating adoption for wearable devices and cold-chain applications due to break resistance and weight reduction
Others	Niche growth in hybrid coated cartridges and silicone-oil-free interior treatments

Glass Type I borosilicate cartridges remain the default specification for insulin pens and most biologic delivery devices. Engineering plastics are carving out high-growth niches where glass breakage poses safety or logistical risks, particularly in home-use wearable on-body delivery systems.

By Delivery Device Compatibility

Sub-Segment	Key Trend
Reusable Pen Injectors	Dominant platform sustained by the global installed base of insulin pens exceeding 500 million devices
Autoinjectors	Growing as biologic self-administration expands beyond insulin into immunology and oncology
Wearable On-Body Pumps	Fastest-growing device interface driven by large-volume (>3 mL) biologic formulations
Disposable Pen Injectors	Cost-competitive option gaining traction in price-sensitive emerging markets

Reusable pen injectors anchor the largest share of cartridge demand, while wearable on-body pumps represent the most dynamic growth vector as drug formulations increasingly exceed the volumetric limits of traditional pen devices.

By Capacity

Sub-Segment	Key Trend
Below 3 mL	Standard format for insulin and most small-molecule injectables
3 mL–5 mL	Mid-volume format gaining share with GLP-1 and monoclonal antibody therapies
5 mL–10 mL	Expanding format for high-viscosity biologics and combination therapies
Above 10 mL	Fastest-growing capacity tier aligned with on-body pump delivery systems

Sub-3 mL cartridges dominate unit volumes, but the shift toward high-concentration biologic formulations is driving outsized growth in larger capacity tiers, particularly the above-10 mL segment designed for wearable devices.

By Therapeutic Area

Sub-Segment	Key Trend
Diabetes	Largest therapeutic segment driven by global insulin pen cartridge consumption
Oncology	Fastest-growing segment as antibody-drug conjugates migrate to subcutaneous cartridge delivery
Autoimmune Diseases	Steady demand from TNF-inhibitor and interleukin-inhibitor pen platforms
Ophthalmology	Emerging cartridge-device combinations for sustained intravitreal delivery
Others	Includes hormonal therapies, rare diseases, and vaccine reconstitution applications

Diabetes maintains the largest volume share, but oncology is rapidly scaling as pharmaceutical companies reformulate IV-administered ADCs for cartridge-compatible subcutaneous injection.

By End User

Sub-Segment	Key Trend
Pharmaceutical Cartridges Market Companies	In-house fill-finish operations consume the majority of cartridge output globally
CMOs/CDMOs	Fastest-growing end-user segment driven by the outsourcing of biologic fill-finish operations
Research Institutions	Small but stable demand for clinical-trial-grade cartridge supply

Large pharmaceutical companies dominate procurement, but the structural shift toward outsourced fill-finish manufacturing is positioning CMOs and CDMOs as the most dynamic demand channel for cartridge suppliers through 2035.

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”